001008614 001__ 1008614
001008614 005__ 20240202202645.0
001008614 0247_ $$2doi$$a10.3390/ijms24119260
001008614 0247_ $$2ISSN$$a1422-0067
001008614 0247_ $$2ISSN$$a1661-6596
001008614 0247_ $$2Handle$$a2128/34585
001008614 0247_ $$2pmid$$a37298211
001008614 0247_ $$2WOS$$aWOS:001005642900001
001008614 037__ $$aFZJ-2023-02431
001008614 082__ $$a540
001008614 1001_ $$0P:(DE-HGF)0$$aAnglada-Huguet, Marta$$b0
001008614 245__ $$aReversal of Tau-Dependent Cognitive Decay by Blocking Adenosine A1 Receptors: Comparison of Transgenic Mouse Models with Different Levels of Tauopathy
001008614 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2023
001008614 3367_ $$2DRIVER$$aarticle
001008614 3367_ $$2DataCite$$aOutput Types/Journal article
001008614 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706854750_18884
001008614 3367_ $$2BibTeX$$aARTICLE
001008614 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001008614 3367_ $$00$$2EndNote$$aJournal Article
001008614 520__ $$aThe accumulation of tau is a hallmark of several neurodegenerative diseases and is associatedwith neuronal hypoactivity and presynaptic dysfunction. Oral administration of the adenosineA1 receptor antagonist rolofylline (KW-3902) has previously been shown to reverse spatial memorydeficits and to normalize the basic synaptic transmission in a mouse line expressing full-lengthpro-aggregant tau (TauDK) at low levels, with late onset of disease. However, the efficacy of treatmentremained to be explored for cases of more aggressive tauopathy. Using a combination of behavioralassays, imaging with several PET-tracers, and analysis of brain tissue, we compared the curativereversal of tau pathology by blocking adenosine A1 receptors in three mouse models expressingdifferent types and levels of tau and tau mutants. We show through positron emission tomographyusing the tracer [18F]CPFPX (a selective A1 receptor ligand) that intravenous injection of rolofyllineeffectively blocks A1 receptors in the brain. Moreover, when administered to TauDK mice, rolofyllinecan reverse tau pathology and synaptic decay. The beneficial effects are also observed in a line withmore aggressive tau pathology, expressing the amyloidogenic repeat domain of tau (TauRDDK) withhigher aggregation propensity. Both models develop a progressive tau pathology with missorting,phosphorylation, accumulation of tau, loss of synapses, and cognitive decline. TauRDDK causespronounced neurofibrillary tangle assembly concomitant with neuronal death, whereas TauDK accumulatesonly to tau pretangles without overt neuronal loss. A third model tested, the rTg4510line, has a high expression of mutant TauP301L and hence a very aggressive phenotype starting at~3 months of age. This line failed to reverse pathology upon rolofylline treatment, consistent with ahigher accumulation of tau-specific PET tracers and inflammation. In conclusion, blocking adenosineA1 receptors by rolofylline can reverse pathology if the pathological potential of tau remains below athreshold value that depends on concentration and aggregation propensity.
001008614 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001008614 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x1
001008614 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001008614 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b1
001008614 7001_ $$0P:(DE-HGF)0$$aSydow, Astrid$$b2
001008614 7001_ $$0P:(DE-HGF)0$$aHilgers, Ronja$$b3
001008614 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b4$$ufzj
001008614 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b5$$ufzj
001008614 7001_ $$0P:(DE-HGF)0$$aKaniyappan, Senthilvelrajan$$b6
001008614 7001_ $$0P:(DE-HGF)0$$aMandelkow, Eckhard$$b7
001008614 7001_ $$0P:(DE-HGF)0$$aMandelkow, Eva-Maria$$b8$$eCorresponding author
001008614 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms24119260$$gVol. 24, no. 11, p. 9260 -$$n11$$p9260 -$$tInternational journal of molecular sciences$$v24$$x1422-0067$$y2023
001008614 8564_ $$uhttps://juser.fz-juelich.de/record/1008614/files/ijms-24-09260.pdf$$yOpenAccess
001008614 909CO $$ooai:juser.fz-juelich.de:1008614$$pdriver$$pVDB$$popen_access$$pdnbdelivery$$popenaire
001008614 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b1$$kFZJ
001008614 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b4$$kFZJ
001008614 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b5$$kFZJ
001008614 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001008614 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
001008614 9141_ $$y2023
001008614 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
001008614 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001008614 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
001008614 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-25
001008614 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001008614 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-25
001008614 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
001008614 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
001008614 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
001008614 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
001008614 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
001008614 920__ $$lyes
001008614 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001008614 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
001008614 980__ $$ajournal
001008614 980__ $$aVDB
001008614 980__ $$aI:(DE-Juel1)INM-5-20090406
001008614 980__ $$aI:(DE-Juel1)INM-2-20090406
001008614 980__ $$aUNRESTRICTED
001008614 9801_ $$aFullTexts